Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China.
Int J Oncol. 2014 Apr;44(4):1335-40. doi: 10.3892/ijo.2014.2296. Epub 2014 Feb 11.
This meta-analysis was designed to assess the overall performance of GnRHa in preserving the ovarian function in young women undergoing chemotherapy. Electronic literature databases including Pubmed, MEDLINE, Cochrane library, Embase, CNKI and Wanfang were searched for articles published till November, 2013. The articles written in both Chinese and English were considered. Only randomized controlled trials (RCTs) were selected. Main Outcome Measure was evaluated by assessing the post‑chemotherapy ovarian function. A random-effects model was used to calculate the risk ratio (RR) and associated 95% confidence intervals (95% CI). Out of the eight RCTs including 621 patients, 321 women were treated with GnRHa during chemotherapy, 9.66% of whom suffered premature ovarian failure (POF). On the other hand, 26.67% of the remaining 300 women suffered POF. More women treated without GnRHa experienced post-chemotherapy POF, yielding an RR of 0.45 [chemotherapy plus GnRHa vs. chemotherapy alone, 95% confidence interval (CI) (0.22, 0.92)]. Based on the available studies, GnRHa plays an important role in the prevention of post-chemotherapy POF, but does not exhibit its protective effects in fertility.
本荟萃分析旨在评估 GnRHa 在保护接受化疗的年轻女性卵巢功能方面的总体疗效。检索了截至 2013 年 11 月的 Pubmed、MEDLINE、Cochrane 图书馆、Embase、CNKI 和万方等电子文献数据库，纳入中英文文献。仅选择随机对照试验（RCT）。主要观察指标为评估化疗后卵巢功能。采用随机效应模型计算风险比（RR）及其 95%置信区间（95%CI）。纳入的 8 项 RCT 共 621 例患者，其中 321 例在化疗期间使用 GnRHa 治疗，9.66%发生卵巢早衰（POF）。而剩余的 300 例患者中，有 26.67%发生 POF。未使用 GnRHa 治疗的患者发生化疗后 POF 的比例更高，RR 为 0.45[化疗加 GnRHa 与单纯化疗相比，95%CI（0.22，0.92)]。基于现有研究，GnRHa 在预防化疗后 POF 方面发挥重要作用，但对生育力无保护作用。
